𝔖 Bobbio Scriptorium
✦   LIBER   ✦

1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

✍ Scribed by Liaw, Y.-F.; Raptopoulou-Gigi, M.; Cheinquer, H.; Sarin, S.K.; Tanwandee, T.; Leung, N.; Peng, C.-Y.; Myers, R.P.; Brown, R.S.; Tsai, N.; Bialkowska, J.; Tang, S.; Cooney, E.


Book ID
121979602
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
67 KB
Volume
52
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Efficacy of entecavir in patients with c
✍ Ju Hyun Shim; Dong Jin Suh; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa C πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 287 KB πŸ‘ 1 views

Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/